NEW YORK, Sept. 26, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousand by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as -
Abbott Laboratories
Abbott Molecular, Inc.
Becton, Dickinson and Company
bioMérieux SA
Cepheid
Read the full report: http://www.reportlinker.com/p090566-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. OUTLOOK.............. II-1 Global In-Vitro Diagnostics (IVD) Market on a Steady Growth Path II-1 Table 1: Global In-Vitro Diagnostics Market by Segment (2015): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Hemostasis (includes corresponding Graph/Chart)..............II-2
Table 2: Global In-Vitro Diagnostics Market by Geographic Region (2015): Percentage Breakdown of Value Sales for the United States, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart) II-2 Molecular Diagnostics - A Rapidly Expanding Segment of the IVD Market.............. II-2 PCR Technology Leads the MDx Market II-4 Current and Future Analysis..............II-5 US and Europe - Leaders in Molecular Diagnostics Adoption II-5 Developing Countries Excel in Growth Prospects II-6 Major Growth Drivers..............II-7 Key Market Trends in a Nutshell..............II-8 Major Technology Trends..............II-8 Advancements in Molecular Diagnostics - A Boon for the Industry II-8 Major Issues and Challenges..............II-9 Market Outlook.............. II-9
2. GROWTH DRIVERS AND MARKET TRENDS..............II-13 Aging Population Drives Molecular Diagnostics Market II-13 Global Aging Population Statistics - Opportunity Indicators II-13 Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart).............. II-13
Table 4: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart) II-14
Table 5: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)..............II-15 Technological Innovations Set to Drive the Market II-15 The Role of Molecular Diagnostics in Personalized Medicine II-16 Companion Diagnostics Make Way for Personalized Medicine II-17 List of Select FDA-Cleared Companion Diagnostic Devices II-18 Biomarkers as Companion Diagnostics II-19 Rise in Healthcare Spending in Developing Nations Bode Well for Market Growth..............II-19 Table 6: Select Countries with Healthcare Spending as a Percentage of GDP (2014) (includes corresponding Graph/Chart) II-20 Proteomics Technologies: Growing in Significance II-20 New Developments in Proteomics Technologies II-21 New Applications Hold Promising Potential II-22 Molecular Diagnostics for Lymphoid Malignancies II-23 Next-Generation Sequencing Technologies Keep Up the Momentum II-23 Select Commercial NGS Technologies II-24 Rising Emphasis on Lab Automation to Augur Well for Market Growth II-24 List of Fully Automated and Rapid Molecular Diagnostics II-26 Molecular Diagnostics and Intellectual Property II-26 Molecular Diagnostics - Moving from Centralization to Decentralization.............. II-26 Limited Reimbursements by Third Party Payers - A Stumbling Block II-27
3. APPLICATION AREAS OF MOLECULAR DIAGNOSTICS II-28 Infectious Diseases.............. II-28 Table 7: World Molecular Diagnostics Market for Infectious Diseases by Test Type: Percentage Share Breakdown for the Year 2015 (includes corresponding Graph/Chart) II-28 Bright Prospects Ahead for Molecular Diagnostics for Testing Infectious Diseases..............II-29 Leading Players.............. II-30 Key Trends.............. II-30 Increasing Incidence of Infectious Diseases Fuels Adoption II-30 Table 8: Reported Cases of Major Infections by Select Geographic Region: 2011..............II-31 Rising Incidence of Hospital Acquired Infections Propels Market Growth.............. II-32 Table 9: Comparison of Different Parameters for Select C. diff MDx Tests.............. II-33 Rising HIV Prevalence Provides Ample Growth Opportunities II-33 Table 10: HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart) II-34
Table 11: Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart).............. II-34
Table 12: Worldwide AIDS Related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart) II-35
Table 13: HIV Prevalence (%) in Adults (15-49 years) by Year: Prevalence Percentage in Adults in 1990, 2000, 2008 & 2014 (includes corresponding Graph/Chart) II-35 Infectious Disease Testing - A Major Driver of Molecular Diagnostics Market..............II-36 Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases..............II-37 Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market.............. II-40 Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing.............. II-41 HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing Market..............II-42 List of Select HPV Molecular Diagnostic Tests by Company and Technique.............. II-43 Cervical Cancer: Rising Incidence & Mortality Enhances Need for Testing.............. II-43 Major Risk Factors to HPV/Cervical Cancer II-45 Table 14: Number of New Cervical Cancer Cases in the World by Region and Age Group (2012) (includes corresponding Graph/Chart).............. II-45
Table 15: World Age-Standardized Cervical Cancer Incidence Rates (2012): Breakdown by Region (includes corresponding Graph/Chart).............. II-46
Table 16: Worldwide Cervical Cancer Mortality by Leading Countries (2012): Ranked by Number of Deaths (in '000s) (includes corresponding Graph/Chart) II-46 HPV Testing for Primary Screening Indication Bodes Well for the Market's Growth..............II-47 Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular Diagnostics..............II-48 List of Select Commercially-Available TB Diagnostics II-49 An Overview of Select TB Diagnostics under Development II-49 Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential..............II-49 PCR Plays a Vital Role in the Diagnosis of Infectious Diseases II-50 Blood Screening.............. II-51 Molecular based Tests Ingrain Roots in Blood Donor Screening Segment.............. II-51 Cancer Screening & Diagnosis..............II-52 Overview.............. II-52 Molecular Tests Lead the Way for Cancer IVD Market Growth II-53 Molecular Markers to Enhance Thyroid Cancer Diagnosis II-53 Oncology-Based Molecular Diagnostics: The Propitious Segment II-54 List of US-FDA Approved Biomarkers for Cancer II-56 Table 17: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart).............. II-57
Table 18: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart) II-58
Table 19: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart).............. II-59 Growing Popularity of Chemo-Sensitivity Testing of CTCs II-59 Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers.............. II-60 Other Testing Applications..............II-60 Genetic Disease Testing Applications II-60 Overview.............. II-60 Pharmacogenomics - Prognosis Based on Genomics II-61 Pharmacogenomics Development Augurs Growth of Genetic Testing Market.............. II-62 Prospects for Genetic Diagnostics and Testing Grow Brighter II-62 List of Select FDA-Cleared Genetic Tests by Disease II-64 Genetic Testing - An Indispensible Tool for Cystic Fibrosis II-64 Table 20: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart) II-65 Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions.............. II-66 Non-Invasive Prenatal Diagnostics - The Way Ahead II-66 Nucleic Acid Amplification Methods for Detection of Antimicrobial Resistance..............II-66 PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents..............II-67 Histocompatibility Testing..............II-67 Table 21: Global HLA Testing Market: Revenue Estimates for 2012 through 2016 (in US$ Million) (includes corresponding Graph/Chart).............. II-67
4. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET II-68 An Overview of Competitive Landscape in Molecular Diagnostics II-68 Table 22: Global Molecular Diagnostics Market by Leading Player (2015): Percentage Share Breakdown by Value Sales for Roche, Qiagen, Abbott, GenProbe, Siemens, and Others (includes corresponding Graph/Chart) II-68 Other Noteworthy Companies and their Competitive Position by Segment.............. II-69 Key Players and Their Technologies II-69 The Top Tier.............. II-69 Mid-Sized and Small Companies..............II-70 Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market.............. II-70 Table 23: Price Comparison of Select Fully Automated and Rapid Molecular Diagnostics..............II-71 Qiagen: The Leading Player in the Global HPV MDx Market II-71 Comparative Analysis of Select HPV MDx Tests II-72 Competitive Dynamics in the C. difficile Testing Market II-72 Table 24: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2015): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian, and Others (includes corresponding Graph/Chart) II-72 List of Select Molecular C. difficile Test Products II-73 Competition in the Blood Screening MDx Market II-73 Table 25: Global Blood Screening MDx Market by Leading Players (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Roche, and Others (includes corresponding Graph/Chart).............. II-73 Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market..............II-73 Competitive Landscape in the Global RT-PCR Market II-74 Table 26: Leading Players in Global RT-PCR Instruments Market (2012): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players - Thermo Fischer, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart)..............II-74 Select Real-Time PCR Products by Company II-75 Competition Heats Up in dPCR Market II-75 Table 27: Leading dPCR Systems At a Glance II-76 Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market.............. II-76 Consolidation Activity Continues to Strengthen Driven by New Entrants.............. II-77 Major M&A Transactions in Molecular Diagnostics: 2011-2016 II-78 Product Marketing - Key to Commercial Success II-79
5. PRODUCT & TECHNOLOGY OVERVIEW..............II-80 Molecular Diagnostics - Definition & Scope II-80 Molecular Diagnostics - Impact on Healthcare II-80 Utility of Molecular Diagnostic Tests II-81 Background of Molecular Diagnostics II-81 Major Milestones in the Evolution of Molecular Diagnostics II-82 Types of Molecular Diagnostics..............II-83 Conventional Diagnostics Vs. Molecular Diagnostics II-83 Unabated Developments in Molecular Diagnostics Technology II-83 Signal Amplification Technologies II-84 PCR - New Developments..............II-84 Quantitative Real-Time PCR for Molecular Diagnostics II-85 Signal Detection and Quantification II-85 Quantitative Real-Time RT-PCR Analysis II-85 Applications of Quantitative Real-Time PCR Analysis II-85 Digital PCR.............. II-86 Non-PCR Methods.............. II-86 Other Signal Amplification Technologies II-86 DNA Probe Based Products..............II-87 Direct Detection of Specific Nucleic Acid Sequences II-87 Nucleic Acid Amplification and Detection II-87 DNA Sequencing and Gene Detection II-88 Arrays of Immobilized Probes (DNA Chips) in Gene Detection II-88 RNA Diagnostics.............. II-88 Complementary Molecular Diagnostic Technologies II-89 Fluorescent In-Situ Hybridization (FISH) II-89 DNA Biochips/Microarrays..............II-89 Biosensors.............. II-90 Proteomic Technologies for Molecular Diagnostics II-90 Nanotechnology for Molecular Diagnostics II-91 Technologies on the Anvil..............II-91 Haplotype Analysis - A Distant Possibility II-91 Chronic Multi-Gene Defects Now Diagnosable II-92 Whole Genome Sequencing - A Boon or a Bane to Genetic Testing? II-92
6. PRODUCT APPROVALS/INTRODUCTIONS II-93 Qiagen Introduces New Diagnostic Test for Cervical Cancer II-93 GE Showcases Discovery MI and Discovery NM/CT 670 CZT II-93 Quest Launches New Tests for Determining Hereditary Cancer II-93 Predictive Launches Test for Spine Deformities II-93 LabCorp® Introduces Epi proColon® II-93 Agena Rolls Out MassARRAY® Dx..............II-93 Rosetta Introduces Three New Diagnostic Offerings II-93 bioMérieux Rolls Out GENE-UP®..............II-94 Roche Introduces New cobas Range II-94 Quest Launches Dako's PD-L1 Complementary Diagnostic Test II-94 Quest Introduces Dako's PD-L1 Tests for KEYTRUDA® II-94 Clarient Rolls Out PD-L1 Test for KEYTRUDA® II-94 Pathway Unveils CancerIntercept™ II-94 Cepheid Unveils Xpert® Carba-R update II-94 Cepheid Launches GeneXpert® Omni II-94 AlphaImpactRx Introduces BrandImpactDx II-95 BioNTech AG Introduces MammaTyper® II-95 EKF Showcases Molecular Diagnostics Products Series II-95 Microbix Unveils New Molecular Diagnostics Range II-95 Roche Introduces cobas® Liat System II-95 Quest Unveils BRCAvantage Plus II-95 Cepheid Rolls Out Xpert® TV..............II-95 OpGen Introduces Acuitas™ MDRO Gene Test II-95 DaVita Introduces Molecular Diagnostic Testing II-96 Grifols Obtains CE-Marking for ID CORE XT Molecular Diagnostic Kit.............. II-96 QIAGEN Rolls Out careHPV™ Test in India II-96 QIAGEN Gets PMA Approval from the US FDA for artus® CMV RGQ MDx Kit.............. II-96 Alere Obtains FDA Approval for Alere™ i Influenza A and B Test II-96 Qiagen Obtains Approval from the US Health Regulators for Gene-Testing Kit.............. II-96 Immucor Obtains the US FDA Approval for PreciseType HEA Test II-97 Biocartis Introduces Idylla™..............II-97 Roche Introduces cobas 6800/8800 Systems II-97 Roche Unveils CINtec PLUS*..............II-97 Roche Rolls Out cobas® HIV-1 and cobas HCV assays II-97
7. RECENT INDUSTRY ACTIVITY..............II-98 Bio-Techne to Acquire Advanced Cell Diagnostics II-98 Myriad Acquires Sividon Diagnostics II-98 Siemens Acquires Neo New Oncology II-98 Luminex to Acquire Nanosphere..............II-98 DiaSorin Completes Acquisition of Focus Diagnostics II-98 Avant Acquires Amarantus Diagnostics II-98 HTG to Collaborate With Bristol-Myers Squibb II-98 Miroculus to Acquire Kapplex..............II-99 Cepheid's Xpert® MRSA NxG Gets European Approval II-99 SpeeDx Collaborates with Goffin Molecular II-99 FDA Approves BD's Totalys™..............II-99 CE Mark Approves BioFire Diagnostics' FilmArray® II-99 Thermo Fisher Acquires Affymetrix II-99 Qiagen Collaborates with Mirati..............II-99 BioGenex to Commence Operations from India Center II-99 Illumina Collaborates with investors to Launch GRAIL II-100 Thermo Fisher Collaborates with Karolinska Institute II-100 CE Mark Approves Aptima® HCV Quant Dx Assay by Hologic II-100 FDA Approves BioFire Diagnostics' FilmArray® II-100 ERBA Acquires Lumora..............II-100 Seegene Collaborates with BD Life Sciences II-100 MDxHealth to Acquire NovioGendix II-100 Quest's Simplexa HSV 1 & 2 Test Gets FDA 510(k) Approval II-100 Burning Rock Partners with Illumina II-101 GE's Low Dose CT Screening Approved by FDA II-101 Roche to Acquire GeneWEAVE BioSciences II-101 Cancer Genetics Acquires Response Genetics, Inc II-101 OpGen Acquires AdvanDx..............II-101 Hitachi Collaborates with QIAGEN II-101 OPKO Takes Over Bio-Reference Laboratories II-101 Sysmex Signs Agreement with IndivuTest II-101 CE Mark Approves Xpert® HIV-1 Qual by Cepheid and FIND II-102 Xpert® HCV Viral Load by Cepheid gets CE Mark Approval II-102 Rosetta Acquires CynoGen..............II-102 Microbix Signs Agreement with Microbiologics II-102 Cepheid Receives Emergency Use Authorization by FDA for Ebola Test.............. II-102 Novigenix Acquires Colox®..............II-102 Roche Takes Over Signature Diagnostics II-102 CE Mark Approves QIAGEN's Circulating Tumor DNA Test II-102 Amarantus Completes Acquisition of DioGenix II-103 Aegis Acquires Diagnovus..............II-103 Empire Announces Acquisition of ID Labs II-103 OncoGxSelect™ Receives NJDH Approval II-103 Roche Takes Over Ariosa..............II-103 FDA Approves Xpert® Norovirus by Cepheid II-103 Cepheid's Xpert® Flu/RSV XC Gets FDA Approval II-103 Roche's cobas® Strep A Test Receives 510(k) Clearance II-103 PDI Takes Over RedPath..............II-104 Veracyte Acquires Allegro Diagnostics II-104 GTCR Takes Over XIFIN..............II-104 QIAGEN to Collaborate with AstraZeneca II-104 BD Collaborates with MD Anderson Cancer Center II-104 Roche Acquires IQuum..............II-104 Myriad to Acquire Crescendo Bioscience II-104 Co-Diagnostics Unveils Co-Dx™..............II-104 bioMérieux Acquires BioFire Diagnostics II-105 Thermo Fisher Scientific Acquires Life Technologies II-105 Myriad Genetics Takes Over Crescendo Bioscience II-105 AUT University Collaborates with Roche Diagnostics II-105 Corgenix Medical Obtains NIH Grant to Advance Development of Ebola Rapid Diagnostic Test Kit II-105 Cepheid Collaborates with AstraZeneca, Cubist Pharmaceuticals and GSK.............. II-105 B Braun US and CeGaT Join Forces to Establish B Braun CeGaT II-106 Provista Diagnostics Expands Exclusive License Agreement for Certain Biomarker and Autoantibody Technologies II-106 Veracyte and Fleury Partner to Offer the Afirma® Gene Expression Classifier..............II-106 Integrated Diagnostics Attracts Financing for Xpresys Lung Molecular Diagnostic Blood Test II-106 MDxHealth Enters into Agreement with Galaxy Health II-106 QIAGEN Acquires Exclusive Worldwide License to CALR Biomarker II-106 Zyomyx Obtains $7.5 Million from UNITAID to Launch MyT4™ POC CD4 Test.............. II-107 Human Longevity Inc. Commences its Operations II-107 Roche Takes Over IQuum..............II-107 Myriad Genetics and Sividon Diagnostics Ink Exclusive Co- Marketing Agreement..............II-107
8. FOCUS ON SELECT PLAYERS..............II-108 Abbott Laboratories (US)..............II-108 Abbott Molecular, Inc. (US)..............II-108 Becton, Dickinson and Company (US) II-109 bioMérieux SA (France)..............II-109 Cepheid (US).............. II-110 F. Hoffmann-La Roche Ltd. (Switzerland) II-111 RMD's Product Portfolio by Segment II-111 RMD's Major Test Offerings by Application II-112 GE Healthcare (US)..............II-112 Grifols International, S.A. (Spain) II-113 Hologic, Inc. (US)..............II-114 QIAGEN N.V. (The Netherlands)..............II-115 Quest Diagnostics, Inc. (US)..............II-116 Siemens Healthcare GmBH (Germany) II-117 Tecan Group Ltd. (Switzerland) II-117 The ELITechGroup SAS (France)..............II-118 Thermo Fisher Scientific (US)..............II-118
9. GLOBAL MARKET PERSPECTIVE..............II-120 Table 28: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) II-120
Table 29: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-121
Table 30: World 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-122 Molecular Diagnostics Market by Application II-123 Table 31: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. II-123
Table 32: World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) II-124
Table 33: World 14-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............II-125
Table 34: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) II-126
Table 35: World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-127
Table 36: World 14-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-128
Table 37: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) II-129
Table 38: World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-130
Table 39: World 14-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............II-131
Table 40: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) II-132
Table 41: World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-133
Table 42: World 14-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............II-134
III. MARKET
1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 US Molecular Diagnostics Market Maintain its Growth Momentum III-1 Competitive Landscape..............III-2 qPCR and dPCR Instrumentation in the US: An Overview III-3 Ageing Demographics: Major Driving Factor III-3 Table 43: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) III-4 Increasing Incidence of Chronic Diseases Drives Focus onto Molecular Diagnostics..............III-4 US Individualized Medicine Market to Witness Significant Growth III-5 Companion Diagnostics Market in the US III-5 List of Select FDA-Cleared Companion Diagnostics III-6 Burgeoning Potential for Genetic Testing III-7 Direct-to-Consumer Testing - A Growing Market III-8 Epidemic Proportion of Cancer in the US - Key Driver for Cancer Genetic Testing..............III-8 Table 44: New Cancer Cases in the US by Gender and Affected Site: 2014 (includes corresponding Graph/Chart) III-9
Table 45: Incidence of Cancer for All Body Sites by Gender & Age Group in the US (2013): New Cancer Cases for Males & Females for the Age Groups Under 45 years; 45 years and Above; Under 65 years; 65 years and Above (includes corresponding Graph/Chart)..............III-10 Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing.............. III-10 List of FDA-Cleared CF MDx Tests III-11 Molecular Diagnostics Tests Gaining Share in STD Testing Domain III-11 HPV Testing Market - A Review..............III-11 Table 46: Prevalence of HPV in the US by Age (includes corresponding Graph/Chart) III-12 Table 47: Prevalence of HPV16 and HPV18 in the US by Cytology (2014) (includes corresponding Graph/Chart) III-12
Table 48: Number of New Cervical Cancer Cases by US State (2015).............. III-13 Competitive Landscape..............III-14 Table 49: Leading Players in the US HPV Testing Market (2013): Percentage Share Breakdown of Revenues for Hologic, QIAGEN, and Others (includes corresponding Graph/Chart).............. III-15 List of FDA Approved HPV MDx Tests III-15 Regulatory Environment..............III-15 FDA Regulations..............III-16 Clinical Laboratory Improvement Amendments (CLIA) III-16 Table 50: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Laboratories by Certificate Type (includes corresponding Graph/Chart) III-18
Table 51: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Labs by Lab Type (includes corresponding Graph/Chart) III-18 Genetic Testing..............III-19 FDA to Implement Strict Measures for Cervical Cancer Screening Tests..............III-19 Limited Reimbursements - A Major Hindrance III-20 New MoPath Codes for Reimbursement for Molecular Diagnostics Tests..............III-20 Product Launches/Approvals..............III-21 Strategic Corporate Developments III-24 Select Key Players..............III-30 B.Market Analytics..............III-37 Table 52: The US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-37
Table 53: The US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-38
Table 54: The US 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-39
2. CANADA.............. III-40 A.Market Analysis.............. III-40 Current and Future Analysis..............III-40 Cancer Incidence in Canada: Opportunity Indicator III-41 Table 55: New Cancer Cases in Canada by Gender and Affected Site: 2014 (includes corresponding Graph/Chart) III-41
Table 56: New Cancer Cases in Canada by Province: 2014 (includes corresponding Graph/Chart) III-42
Table 57: New Cancer Cases in Canada by Age Group: 2014 (includes corresponding Graph/Chart) III-43 Product Approval..............III-43 Strategic Corporate Development III-44 B.Market Analytics..............III-44 Table 58: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-44
Table 59: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-45
Table 60: Canadian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-46
3. JAPAN.............. III-47 A.Market Analysis.............. III-47 Current and Future Analysis..............III-47 Demographics Drive Market Growth III-47 Table 61: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart) III-47 Strategic Corporate Development III-48 B.Market Analytics..............III-48 Table 62: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-48
Table 63: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-49
Table 64: Japanese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-50
4. EUROPE.............. III-51 A.Market Analysis.............. III-51 Current and Future Analysis..............III-51 Insight into Molecular Diagnostics Markets in Europe III-52 Table 65: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart) III-52 Increasing Testing Needs of the Elderly: Business Case for Molecular Diagnostics..............III-53 Table 66: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)..............III-53 PCR Reagents in Europe: An Overview III-54 Automated Systems Gain Preeminence III-54 Oncology-based Molecular Diagnostics Holds Immense Potential III-54 Table 67: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart) III-55 European Personalized Medicine Market to Exhibit Robust Growth III-56 HPV Testing in Europe: An Overview III-56 Table 68: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Normal Cytology (includes corresponding Graph/Chart) III-56
Table 69: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Low-Grade Lesions (includes corresponding Graph/Chart) III-57
Table 70: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with High-Grade Lesions (includes corresponding Graph/Chart) III-57
Table 71: HPV Testing Market in Europe by Region (2014): Breakdown by Number of Women Tested with Cervical Cancer (includes corresponding Graph/Chart) III-58 List of Select CE-Marked HPV Molecular Diagnostic Tests III-58 Cervical Cancer Screening in Europe - A Review III-59 Table 72: Key Facts on Cervical Cancer in Europe: 2014 (includes corresponding Graph/Chart) III-60
Table 73: Cervical Cancer Incidence and Mortality in European Countries (2012)..............III-61
Table 74: Prevalence of Cervical Cancer in European Countries (2012).............. III-62
Table 75: European HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart) III-63 Strategic Corporate Developments III-63 B.Market Analytics..............III-64 Table 76: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-64
Table 77: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-65
Table 78: European 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-66
Table 79: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-67
Table 80: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-68
Table 81: European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-69
4a. FRANCE.............. III-70 A.Market Analysis.............. III-70 Current and Future Analysis..............III-70 Product Launch.............. III-70 Strategic Corporate Developments III-70 Select Key Players..............III-71 B.Market Analytics..............III-73 Table 82: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-73
Table 83: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-74
Table 84: French 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-75
4b. GERMANY.............. III-76 A.Market Analysis.............. III-76 Current and Future Analysis..............III-76 Product Launches..............III-76 Strategic Corporate Developments III-77 Siemens AG - A Key Player..............III-77 B.Market Analytics..............III-79 Table 85: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-79
Table 86: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-80
Table 87: German 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-81
4c. ITALY.............. III-82 A.Market Analysis.............. III-82 Current and Future Analysis..............III-82 Strategic Corporate Development III-82 B.Market Analytics..............III-83 Table 88: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-83
Table 89: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-84
Table 90: Italian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-85
4d. THE UNITED KINGDOM..............III-86 A.Market Analysis.............. III-86 Current and Future Analysis..............III-86 SMIP for Pharmacogenomic Testing III-86 B.Market Analytics..............III-87 Table 91: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-87
Table 92: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-88
Table 93: The UK 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-89
4e. SPAIN.............. III-90 A.Market Analysis.............. III-90 Current and Future Analysis..............III-90 Spain - Poised to become a Reckoning Force in Personalized Medicines.............. III-90 Strategic Corporate Development III-90 Grifols International, S.A. - A Key Player III-91 B.Market Analytics..............III-92 Table 94: Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-92
Table 95: Spanish Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-93
Table 96: Spanish 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-94
4f. RUSSIA.............. III-95 Market Analysis.............. III-95 Table 97: Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-95
Table 98: Russian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-96
Table 99: Russian 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-97
4g. REST OF EUROPE.............. III-98 A.Market Analysis.............. III-98 Current and Future Analysis..............III-98 Product Launches/Approvals..............III-98 Strategic Corporate Developments III-99 Key Players.............. III-100 B.Market Analytics..............III-103 Table 100: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-103
Table 101: Rest of European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-104
Table 102: Rest of European 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-105
5. ASIA-PACIFIC.............. III-106 A.Market Analysis.............. III-106 Current and Future Analysis..............III-106 Healthcare Spending in Asia-Pacific: On the Rise III-106 In-vitro Diagnostics Market: India & China Offer Significant Growth Opportunities..............III-106 Table 103: China and India Leads Global Population (July 2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart) III-107
Table 104: Age-wise Breakup of China and India's Population Vis-à-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart) III-108 Molecular Diagnostics Testing Opens New World of Possibilities III-108 Recent Advancements in Molecular Diagnostics Market: A Quick Review.............. III-109 Novel Genetic Testing Methods III-109 Development of Personalized Healthcare Approaches III-109 Molecular Painting for Genetic Diagnosis of Diseases III-110 New Technique to Detect H1N1 Virus III-110 B.Market Analytics..............III-111 Table 105: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-111
Table 106: Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-112
Table 107: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. III-113
Table 108: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-114
Table 109: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-115
Table 110: Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-116
5a. CHINA.............. III-117 A.Market Analysis.............. III-117 Current and Future Analysis..............III-117 In-Vitro Diagnostics Market on the Growth Curve III-117 HPV Testing in China: An Overview III-117 Government Support Drives Personalized Medicine Market in China III-118 Strategic Corporate Development III-118 B.Market Analytics..............III-119 Table 111: Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-119
Table 112: Chinese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-120
Table 113: Chinese 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-121
5b. REST OF ASIA-PACIFIC..............III-122 A.Market Analysis.............. III-122 Current and Future Analysis..............III-122 A Focus on the Indian Molecular Diagnostics Market III-122 Molecular Diagnostic Market in India to Witness Significant Growth.............. III-122 Growth Drivers in a Nut Shell III-123 Growing Investments in Pharmacogenomics Research Drives Personalized Medicine..............III-124 Indian Scientific Research towards Functional Genomics and Proteomics.............. III-124 Automation - The Emerging Trend in IVD Industry III-125 Growing Investments in Pharmacogenomics Research Drives Personalized Medicine..............III-126 HPV Testing Market: An Overview III-126 Table 114: HPV in India - Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart) III-127 Product Launche/Approval..............III-128 Strategic Corporate Developments III-128 B.Market Analytics..............III-129 Table 115: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-129
Table 116: Rest of Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-130
Table 117: Rest of Asia-Pacific 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-131
6. LATIN AMERICA.............. III-132 A.Market Analysis.............. III-132 Current and Future Analysis..............III-132 Brazilian IVD Market on the Rise III-132 B.Market Analytics..............III-133 Table 118: Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-133
Table 119: Latin American Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-134
Table 120: Latin American 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-135
7. REST OF WORLD.............. III-136 A.Market Analysis.............. III-136 Current and Future Analysis..............III-136 Product Launch.............. III-136 B.Market Analytics..............III-137 Table 121: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-137
Table 122: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-138
Table 123: Rest of World 14-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-139
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 145 (including Divisions/Subsidiaries - 162)
The United States (99) Canada (2) Europe (50) - France (5) - Germany (11) - The United Kingdom (12) - Italy (2) - Spain (1) - Rest of Europe (19) Asia-Pacific (Excluding Japan) (10) Middle East (1)
Read the full report: http://www.reportlinker.com/p090566-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
